Has the South Korean Packaged Foods and Meats Industry valuation changed over the past few years?

Investors are relatively neutral on the industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PE ratio of 13.0x.

How does South Korean Packaged Foods and Meats compare with similar industries?

There is insufficient data on the sub-industries of this industry.

South Korean (KOSPI) Packaged Foods and Meats Industry Analysis

Date	Market Cap	Revenue	Earnings	PE
Fri, 13 May 2022	₩29.3t	₩96.7t	₩2.8t	11.4x
Sun, 10 Apr 2022	₩29.0t	₩96.6t	₩2.8t	10.3x
Tue, 08 Mar 2022	₩27.1t	₩92.7t	₩2.7t	10.9x
Thu, 03 Feb 2022	₩26.9t	₩92.7t	₩2.7t	10x
Sat, 01 Jan 2022	₩28.8t	₩92.7t	₩2.7t	10.6x
Mon, 29 Nov 2021	₩28.1t	₩92.6t	₩2.7t	10.3x
Wed, 27 Oct 2021	₩30.6t	₩90.2t	₩2.5t	12.8x
Fri, 24 Sep 2021	₩31.2t	₩90.2t	₩2.5t	13.4x
Sun, 22 Aug 2021	₩30.3t	₩90.7t	₩2.6t	13.2x
Fri, 09 Jul 2021	₩33.3t	₩90.7t	₩2.6t	15x
Thu, 01 Apr 2021	₩30.7t	₩88.8t	₩2.4t	12.6x
Sun, 03 Jan 2021	₩28.8t	₩87.5t	₩2.5t	14x
Wed, 07 Oct 2020	₩28.2t	₩86.8t	₩2.5t	10.4x
Tue, 30 Jun 2020	₩28.0t	₩85.4t	₩2.1t	11.9x
Fri, 03 Apr 2020	₩22.0t	₩84.2t	₩1.9t	10.1x
Mon, 06 Jan 2020	₩25.7t	₩82.6t	₩1.5t	14.3x
Thu, 10 Oct 2019	₩25.9t	₩79.8t	₩1.3t	16.9x
Wed, 03 Jul 2019	₩28.1t	₩78.1t	₩1.5t	15.1x


KR Market	-3.28%
Consumer Staples	-2.41%
Food	-1.75%
Packaged Foods and Meats	-1.48%
Agricultural Products	-4.41%

Company	Last Price	7D	1Y	Valuation
A097950 CJ Cheiljedang	₩404.00k	5.5% +₩336.5b	-11.0%	PS10.6x
A271560 ORION	₩92.50k	1.4% +₩51.4b	-23.6%	PS14.2x
A003380 Harim Holdings	₩10.70k	0.9% +₩9.5b	-8.2%	PS3.3x
A311390 Neo Cremar	₩18.05k	6.2% +₩9.1b	102.8%	PS79x
A004370 Nongshim	₩303.00k	0.5% +₩8.7b	0.7%	PS17.6x

Feb 19

Orion Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU

ORION Corp. presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). CYPIDES phase 1 data shows that ODM-208 effectively blocked the production of all steroid hormones in men with metastatic castration-resistant prostate cancer (mCRPC) and showed promising anti-tumor activity in men progressing despite extensive prior treatment with both novel hormonal therapies (NHT's) and taxanes. Treatment responses to ODM-208 especially occurred in men with activating androgen receptor (AR) mutations. ODM-208 is a complete blocker of steroid biosynthesis that suppresses the production of all steroid hormones and their precursors that may activate the androgen receptor (AR) signalling pathway. This is particularly relevant in patients with AR ligand binding domain (LBD) activating somatic point mutations, a mechanism of resistance to hormone-based therapies in metastatic castration-resistant prostate cancer (mCRPC). During treatment the patients receive hormone replacement therapy to ensure sufficient adrenal function. In CYPIDES phase I, a total of 44 patients with median age of 70 years received ODM-208. Overall, 32% of the patients achieved a PSA (prostate specific antigen) decrease of >=50%. Of patients with AR LBD mutation (17), 68% achieved a PSA decrease of >=50%. Also, prolonged treatment responses were observed especially in patients with AR LBD mutation. Although tolerated by most patients, the main safety finding was adrenal insufficiency (AI). Overall, 14 (32%) patients experienced severe adrenal insufficiency despite the replacement therapy requiring further adrenal supplementation after which the ODM-208 treatment commonly continued. Non-adrenal adverse events were unremarkable.Taru Blom (MD, PhD), Vice President, Global Development and CMO, Orion R&D comments: "ODM-208 is a first-in-class CYP11A1-inhibitor and the company is excited that this novel approach works in some of the patients who have only a few effective treatment options available. The first results of CYPIDES are encouraging, and more studies are needed to confirm the potential of ODM-208 as a treatment option for men with advanced prostate cancer.

South Korean (KOSPI) Packaged Foods and Meats Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

A097950

CJ Cheiljedang Reportedly Puts CJ Selecta Up for Sale

A017810

Now 24% undervalued

A145990

Insufficient new directors

A136490

No independent directors

A084690

No independent directors

A027710

Less than half of directors are independent

A003380

Less than half of directors are independent

A000070

Less than half of directors are independent

A006040

Price target increased to ₩400,000

A005610

Less than half of directors are independent

A001130

Less than half of directors are independent

A311390

Investor sentiment deteriorated over the past week

A271560

Orion Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU

A004370

Upcoming dividend of ₩4,000 per share

A218150

Milae Bioresources Co., Ltd. announced that it has received KRW 15 billion in funding

A236030

Ssial Food Inc, Annual General Meeting, Mar 29, 2021